Centralized Pan-South African Survey on the Undertreatment of Hypercholesterolaemia

Centralized Pan-South African Survey on the Undertreatment of Hypercholesterolaemia.

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01027624

Acronym

CEPHEUS

Enrollment

3000

Registered

2009-12-08

Start date

2009-11-30

Completion date

2010-04-30

Last updated

2011-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Undertreatment of Hypercholesterolaemia

Keywords

Pan South African Survey on the Undertreatment of Hypercholesterolaemia

Brief summary

This is a multi-centre survey of patients who are currently on lipid lowering pharmacological treatment in South Africa.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Subject must be 18 years of age or older of either gender or race. * Subject must provide informed consent and comply with the survey procedures. * Subject is on lipid lowering drug treatment for at least 3 months, with no dose change for a minimum of 6 weeks.

Exclusion criteria

* Subjects who are unwilling or unable to provide informed consent.

Design outcomes

Primary

Measure	Time frame
Proportion of patients on lipid-lowering pharmacological treatment reaching LDL-C goals according to NCEP ATP III/Updated 2004 NCEP ATP III	—

Secondary

Measure	Time frame
Proportion of patients on lipid-lowering pharmacological treatment reaching LDL-C goals according to NCEP ATP III/Updated 2004 NCEP ATP III	—
Proportion of patients on lipid-lowering pharmacological treatment reaching LDL-C goals according to the Fourth Joint European Task Force Guidelines/South African Guidelines in primary/secondary prevention patients, patients with metabolic syndrome	—
Proportion of patients on lipid-lowering pharmacological treatment reaching the non HDL-C goals according to NCEP ATP III/Updated 2004 NCEP ATP III Guidelines	—

Countries

South Africa

Outcome results